<!DOCTYPE html>
<html lang="en" data-theme="light">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>Congenital Abnormalities & Fetal Wellbeing | Essential Obstetrics and Gynaecology</title>

    
<!-- Preconnect for performance -->
<link rel="preconnect" href="https://fonts.googleapis.com">
<link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>

<!-- Google Fonts -->
<link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&family=Source+Serif+4:opsz,wght@8..60,400;8..60,600&display=swap" rel="stylesheet">

<!-- Main Stylesheet -->
<link rel="stylesheet" href="../styles/main.css">

<!-- MathJax Configuration -->
<script>
MathJax = {
    tex: {
        inlineMath: [['$', '$'], ['\\(', '\\)']],
        displayMath: [['$$', '$$'], ['\\[', '\\]']],
        processEscapes: true,
        processEnvironments: true,
        tags: 'ams'
    },
    svg: { fontCache: 'global' },
    options: {
        skipHtmlTags: ['script', 'noscript', 'style', 'textarea', 'pre']
    }
};
</script>
<script id="MathJax-script" async src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>

  

</head>
<body>
<!-- Skip Link for Accessibility -->
<a href="#main-content" class="skip-link">Skip to main content</a>
<!-- Reading Progress Bar -->
<div class="reading-progress-container" aria-hidden="true">
    <div class="reading-progress-bar" id="reading-progress"></div>
</div>

<!-- Theme Toggle -->
<button class="theme-toggle" id="theme-toggle" aria-label="Toggle dark mode" title="Toggle dark mode">
    <span class="theme-toggle-icon light-icon">‚òÄÔ∏è</span>
    <span class="theme-toggle-icon dark-icon">üåô</span>
</button>

<div class="page-wrapper">
    <!-- Floating Mini-TOC -->
    <aside class="floating-toc" id="floating-toc" aria-label="On this page">
        <div class="floating-toc-header">
            <span class="floating-toc-icon">üìë</span>
            <span>On this page</span>
        </div>
        <nav class="floating-toc-nav">
            <ul class="floating-toc-list">
                <!-- Will be populated by JS -->
            </ul>
        </nav>
    </aside>

    <div class="container">
        <article class="document-article" role="main" id="main-content">
            <!-- Top Navigation -->
            <nav class="document-nav" role="navigation" aria-label="Document navigation">
                <div class="nav-container">
                    <a href="../index.html" class="nav-button nav-button--toc" aria-label="Table of Contents">
                        <span class="nav-icon">üìö</span>
                        <span class="nav-text">Contents</span>
                    </a>
                    
                    <a href="chapter-09-maternal-medicine.html" class="nav-button nav-button--prev" aria-label="Previous chapter">
                        <span class="nav-icon">‚Üê</span>
                        <span class="nav-text">Previous</span>
                    </a>
                    
                    <div class="document-progress">
                        <div class="progress-indicator">
                            <span class="progress-current">10</span>
                            <span class="progress-separator">/</span>
                            <span class="progress-total">21</span>
                        </div>
                        <div class="progress-bar-container" aria-hidden="true">
                            <div class="progress-bar-fill" style="width: 48%;"></div>
                        </div>
                        <span class="progress-label">Congenital Abnormalities &amp; Fetal Wellbeing</span>
                    </div>
                    
                    <a href="chapter-11-management-labour.html" class="nav-button nav-button--next" aria-label="Next chapter">
                        <span class="nav-text">Next</span>
                        <span class="nav-icon">‚Üí</span>
                    </a>
                </div>
            </nav>

            <!-- Breadcrumb -->
            <nav class="breadcrumb" aria-label="Breadcrumb">
                <ol class="breadcrumb-list">
                    <li class="breadcrumb-item"><a href="../index.html">Home</a></li>
                    <li class="breadcrumb-item"><a href="#">Section 2: Essential Obstetrics</a></li>
                    <li class="breadcrumb-item active" aria-current="page">Chapter 10</li>
                </ol>
            </nav>

            <!-- Document Header -->
            <header class="document-header">
                <div class="header-badge">
                    <span class="badge-icon">üë∂</span>
                    <span class="badge-text">Chapter 10</span>
                </div>
                <h1 class="document-title">Congenital abnormalities and assessment of fetal wellbeing</h1>
                <p class="hero-subtitle">David James and Suzanne V.F. Wallace</p>
            </header>

            <!-- Main Content Area -->
            <div class="content-wrapper">
                
                <!-- Learning Outcomes -->
                <section id="learning-outcomes" class="content-section">
                    <div class="content-card">
                        <h2>Learning outcomes</h2>
                        <p>After studying this chapter you should be able to:</p>
                        
                        <h3>Knowledge criteria</h3>
                        <ul class="enhanced-list">
                            <li class="list-item">
                                <span class="list-marker"></span>
                                <span class="list-content">Describe the common structural abnormalities resulting from abnormal development</span>
                            </li>
                            <li class="list-item">
                                <span class="list-marker"></span>
                                <span class="list-content">List the risk factors for the common fetal abnormalities</span>
                            </li>
                            <li class="list-item">
                                <span class="list-marker"></span>
                                <span class="list-content">Compare the diagnostic tests for fetal abnormality</span>
                            </li>
                            <li class="list-item">
                                <span class="list-marker"></span>
                                <span class="list-content">Describe the role of ultrasound scanning in pregnancy</span>
                            </li>
                            <li class="list-item">
                                <span class="list-marker"></span>
                                <span class="list-content">Describe the aetiology, risk factors and management of rhesus isoimmunization</span>
                            </li>
                        </ul>

                        <h3>Clinical competencies</h3>
                        <ul class="enhanced-list">
                            <li class="list-item">
                                <span class="list-marker"></span>
                                <span class="list-content">Interpret the results of investigations of fetal wellbeing</span>
                            </li>
                            <li class="list-item">
                                <span class="list-marker"></span>
                                <span class="list-content">Plan the investigation and management of the small for gestational age baby</span>
                            </li>
                        </ul>

                        <h3>Professional skills and attitudes</h3>
                        <ul class="enhanced-list">
                            <li class="list-item">
                                <span class="list-marker"></span>
                                <span class="list-content">Reflect on the impact on a family of a diagnosis of fetal abnormality</span>
                            </li>
                        </ul>
                    </div>
                </section>

                <!-- Congenital Abnormalities -->
                <section id="congenital-abnormalities" class="content-section">
                    <div class="section-header">
                        <div class="section-number" aria-hidden="true">01</div>
                        <h2 class="section-title">
                            <span class="title-icon">üß¨</span>
                            CONGENITAL ABNORMALITIES
                        </h2>
                    </div>
                    
                    <div class="content-card">
                        <p>Fetal abnormality is found in:</p>
                        <ul class="enhanced-list">
                            <li class="list-item">
                                <span class="list-marker"></span>
                                <span class="list-content">over 50% of conceptions</span>
                            </li>
                            <li class="list-item">
                                <span class="list-marker"></span>
                                <span class="list-content">about 70% of miscarriages</span>
                            </li>
                            <li class="list-item">
                                <span class="list-marker"></span>
                                <span class="list-content">15% of deaths between 20 weeks gestation and 1 year postnatal</span>
                            </li>
                            <li class="list-item">
                                <span class="list-marker"></span>
                                <span class="list-content">1‚Äì2% of births, including major and minor anomalies (a major abnormality is an abnormality or abnormalities that result in the death of the baby or severe disability)</span>
                            </li>
                            <li class="list-item">
                                <span class="list-marker"></span>
                                <span class="list-content">8% of special needs register/disabled children.</span>
                            </li>
                        </ul>
                        <p>The overall incidence in the UK has fallen over the past three decades due to the introduction of screening programmes in pregnancy, the resultant greater success at diagnosis during pregnancy and parents opting to terminate a pregnancy once a severe abnormality has been diagnosed.</p>
                        <p>The commonest four groups of defects are neural tube defects (3‚Äì7/1000), congenital cardiac defects (6/1000), Down's syndrome (1.5/1000) and cleft lip/palate (1.5/1000) (Table 10.1).</p>

                        <div class="table-wrapper">
                            <div class="table-header">
                                <span class="table-icon">üìä</span>
                                <span class="table-caption">Table 10.1 Major congenital abnormalities</span>
                            </div>
                            <div class="table-container">
                                <table class="content-table">
                                    <thead>
                                        <tr>
                                            <th>Abnormality</th>
                                            <th>Approximate incidence<br>(per 1000 births)</th>
                                        </tr>
                                    </thead>
                                    <tbody>
                                        <tr>
                                            <td>Neural tube defects</td>
                                            <td>3‚Äì7</td>
                                        </tr>
                                        <tr>
                                            <td>Congenital heart disease</td>
                                            <td>6</td>
                                        </tr>
                                        <tr>
                                            <td>Severe mental retardation</td>
                                            <td>4</td>
                                        </tr>
                                        <tr>
                                            <td>Down's syndrome</td>
                                            <td>1.5</td>
                                        </tr>
                                        <tr>
                                            <td>Cleft lip/palate</td>
                                            <td>1.5</td>
                                        </tr>
                                        <tr>
                                            <td>Talipes</td>
                                            <td>1‚Äì2</td>
                                        </tr>
                                        <tr>
                                            <td>Abnormalities of limbs</td>
                                            <td>1‚Äì2</td>
                                        </tr>
                                        <tr>
                                            <td>Deafness</td>
                                            <td>0.8</td>
                                        </tr>
                                        <tr>
                                            <td>Blindness</td>
                                            <td>0.2</td>
                                        </tr>
                                        <tr>
                                            <td>Others, including urinary tract anomalies</td>
                                            <td>2</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Total</strong></td>
                                            <td><strong>15‚Äì30</strong></td>
                                        </tr>
                                    </tbody>
                                </table>
                            </div>
                        </div>

                        <h3>Neural tube defects</h3>
                        <p>The neural tube defects are the commonest of the major congenital abnormalities and include anencephaly, microcephaly, spina bifida with or without myelomeningocele, encephalocele, holoprosencephaly and hydranencephaly (Fig. 10.1). The incidence is approximately 1/200 and the chance of having an affected child after one previous abnormal child is 1/20. Infants with anencephaly or microcephaly do not usually survive. Many die during labour and the remainder within the first week of life. Infants with open neural tube defects often survive, particularly where it is possible to cover the lesion surgically with skin. However, the defect may result in paraplegia and bowel and bladder incontinence. The child often has normal intelligence and becomes aware of the problems posed for the parents. Closed lesions generally do not cause problems and may escape detection until after birth.</p>
                        <p>There is good evidence that pre- and periconceptual folic acid supplementation (400 Œºg/day) reduces the incidence of this condition. Once a woman is pregnant, the major effort is directed toward screening techniques that enable recognition of the abnormality and the offer of a termination of the pregnancy where there is a lethal abnormality.</p>
                        <p>Folic acid dietary supplementation is indicated both before and during pregnancy in those women who have experienced a pregnancy complicated by a neural tube defect.</p>

                        <figure class="content-figure" data-lightbox="true">
                            <div class="figure-image-wrapper">
                                <img src="../assets/images/image-20251213-c6d8fd5d.jpeg" alt="Two common abnormalities of the central nervous system" class="figure-image" loading="lazy">
                                <div class="figure-overlay">
                                    <span class="overlay-icon">üîç</span>
                                    <span class="overlay-text">Click to enlarge</span>
                                </div>
                            </div>
                            <figcaption class="figure-caption">Fig. 10.1 Two common abnormalities of the central nervous system. (A) Anencephaly. (B) Spina bifida with open neural tube defect.</figcaption>
                        </figure>

                        <h3>Congenital cardiac defects</h3>
                        <p>Some of these infants present with intrauterine growth retardation and oligohydramnios, but in many cases the diagnosis is recognised and diagnosed after delivery. With improvements in real-time ultrasound imaging, recognition of many cardiac defects has become possible; however, early recognition is essential if any action is to be taken. A four-chamber view of the fetal heart is shown in Figure 10.2.</p>
                        <p>The most common defects are ventricular and atrial septal defects, pulmonary and aortic stenosis, coarctation and transpositions, including the tetralogy of Fallot. These lesions can generally now be recognized on the fourchamber views recorded during detailed 18-week gestation scans.</p>

                        <figure class="content-figure" data-lightbox="true">
                            <div class="figure-image-wrapper">
                                <img src="../assets/images/image-20251213-d4bd0b06.jpeg" alt="Four-chamber ultrasound view of the fetal heart" class="figure-image" loading="lazy">
                                <div class="figure-overlay">
                                    <span class="overlay-icon">üîç</span>
                                    <span class="overlay-text">Click to enlarge</span>
                                </div>
                            </div>
                            <figcaption class="figure-caption">Fig. 10.2 Four-chamber ultrasound view of the fetal heart.</figcaption>
                        </figure>

                        <h3>Defects of the abdominal wall</h3>
                        <p>Defects of the abdominal wall can be diagnosed by ultrasound imaging. They include gastroschisis and exomphalos (Fig. 10.3). In both cases, the bowel extrudes outside the abdominal cavity. The main differences between the two are that a gastroschisis is a defect that is separate from the umbilical cord (usually 2‚Äì3 cm below and to the right), does not have a peritoneal covering and is usually an isolated problem. In contrast, an exomphalos is essentially a large hernia of the umbilical cord with a peritoneal covering and an increased risk of an underlying chromosomal abnormality,</p>

                        <figure class="content-figure" data-lightbox="true">
                            <div class="figure-image-wrapper">
                                <img src="../assets/images/image-20251213-49783bc9.jpeg" alt="Bowel extrusion associated with exomphalos" class="figure-image" loading="lazy">
                                <div class="figure-overlay">
                                    <span class="overlay-icon">üîç</span>
                                    <span class="overlay-text">Click to enlarge</span>
                                </div>
                            </div>
                            <figcaption class="figure-caption">Fig. 10.3 Bowel extrusion associated with exomphalos.</figcaption>
                        </figure>

                        <h3>Chromosomal abnormalities</h3>
                        <p>A considerable number of chromosomal abnormalities have been identified from the culture and karyotyping of fetal/placental cells in the amniotic fluid or from the chorionic plate. The chromosomal abnormalities include both structural and numerical abnormalities of the karyotype. The commonest abnormality is that associated with trisomy 21 or Down's syndrome.</p>

                        <h4>Down's syndrome</h4>
                        <p>Down's syndrome (DS) is characterized by the typical abnormal facial features (Fig 10.4), mental retardation of varying degrees of severity and congenital heart disease. The karyotype includes an additional chromosome on group 21 ('trisomy 21'; Fig 10.5). The incidence overall is 1.5/1000 births. However, the risk increases with advancing maternal age (see below). The underlying reason is thought to be an increased frequency of non-disjunction at meiosis.</p>
                        <p>About 6‚Äì8% of affected infants have the disease as a result of a translocation and the extra 21 chromosome carried on to another chromosome, usually in group 13‚Äì15. The mother or the father will usually show evidence of being a balanced translocation carrier.</p>

                        <figure class="content-figure" data-lightbox="true">
                            <div class="figure-image-wrapper">
                                <img src="../assets/images/image-20251213-fa1cbc0e.jpeg" alt="Facial appearance of infant with Down's syndrome" class="figure-image" loading="lazy">
                                <div class="figure-overlay">
                                    <span class="overlay-icon">üîç</span>
                                    <span class="overlay-text">Click to enlarge</span>
                                </div>
                            </div>
                            <figcaption class="figure-caption">Fig. 10.4 Facial appearance of infant with Down's syndrome.</figcaption>
                        </figure>

                        <figure class="content-figure" data-lightbox="true">
                            <div class="figure-image-wrapper">
                                <img src="../assets/images/image-20251213-ff9d3c77.jpeg" alt="Trisomy 21 karyotype" class="figure-image" loading="lazy">
                                <div class="figure-overlay">
                                    <span class="overlay-icon">üîç</span>
                                    <span class="overlay-text">Click to enlarge</span>
                                </div>
                            </div>
                            <figcaption class="figure-caption">Fig. 10.5 Trisomy 21 karyotype.</figcaption>
                        </figure>
                    </div>
                </section>

                <!-- Assessing Fetal Normality -->
                <section id="assessing-fetal-normality" class="content-section">
                    <div class="section-header">
                        <div class="section-number" aria-hidden="true">02</div>
                        <h2 class="section-title">
                            <span class="title-icon">üîé</span>
                            ASSESSING FETAL NORMALITY
                        </h2>
                    </div>
                    
                    <div class="content-card">
                        <h3>Screening</h3>
                        <p>Screening in this context is the process whereby women with a higher risk of fetal abnormality are identified in the general population. This screening is undertaken using identification of clinical risk factors, ultrasound (US) and biochemical testing of maternal serum. Clinical risk factors can be identified throughout pregnancy though the options for management are different depending on the gestational age. US and biochemical screening is offered to women in the first half of pregnancy. Ideally women should be offered a combined screening test (using US and biochemistry) for DS towards the end of the first trimester and a detailed US scan at about 20 weeks. The early scan also allows gestational age to be confirmed. If a woman presents too late for the first trimester DS screening, then she should be offered a biochemical screening test at about 16 weeks.</p>

                        <h4>Clinical risk factors: early pregnancy</h4>
                        <p>These include:</p>
                        <ul class="enhanced-list">
                            <li class="list-item">
                                <span class="list-marker"></span>
                                <span class="list-content">maternal age and risk of aneuploidy especially DS (see Tables 10.2 and 10.3).</span>
                            </li>
                            <li class="list-item">
                                <span class="list-marker"></span>
                                <span class="list-content">maternal drug ingestion:
                                    <ul style="margin-top: 0.5rem; margin-bottom: 0;">
                                        <li>anticonvulsant drugs (e.g. phenytoin, carbamazepine and sodium valproate) that can produce defects of the central nervous system especially neural tube defects</li>
                                        <li>cytotoxic agents used in cancer therapy or for immunosuppression with organ transplantation are associated with an increased risk of fetal growth restriction</li>
                                        <li>warfarin is teratogenic when used in the first trimester and can produce a fetal bleeding disorder when used later in pregnancy</li>
                                    </ul>
                                </span>
                            </li>
                            <li class="list-item">
                                <span class="list-marker"></span>
                                <span class="list-content">previous history of fetal abnormality:
                                    <ul style="margin-top: 0.5rem; margin-bottom: 0;">
                                        <li>if, for example, a woman has had a DS baby in the past she is at greater risk of recurrence than the risk given by her age alone</li>
                                        <li>however, not all fetal abnormalities are associated with a greater risk of recurrence in a subsequent pregnancy</li>
                                    </ul>
                                </span>
                            </li>
                            <li class="list-item">
                                <span class="list-marker"></span>
                                <span class="list-content">maternal disease (see Chapter 9) including:
                                    <ul style="margin-top: 0.5rem; margin-bottom: 0;">
                                        <li>diabetes: the reported risks of fetal abnormality vary between 3‚Äì8%. This figure is reduced significantly if the diabetes is well controlled before and during the first trimester</li>
                                        <li>congenital heart cardiac disease: a woman who has a congenital cardiac defect has a 1‚Äì2% risk of a cardiac abnormality in her fetus.</li>
                                    </ul>
                                </span>
                            </li>
                        </ul>

                        <div class="table-wrapper">
                            <div class="table-header">
                                <span class="table-icon">üìä</span>
                                <span class="table-caption">Table 10.2 The risk of having a pregnancy affected by Down's syndrome according to maternal age at the time of birth</span>
                            </div>
                            <div class="table-container">
                                <table class="content-table">
                                    <thead>
                                        <tr>
                                            <th>Maternal age at delivery (years)</th>
                                            <th>Risk of Down's syndrome</th>
                                        </tr>
                                    </thead>
                                    <tbody>
                                        <tr><td>15</td><td>1:1578</td></tr>
                                        <tr><td>20</td><td>1:1528</td></tr>
                                        <tr><td>25</td><td>1:1351</td></tr>
                                        <tr><td>30</td><td>1:909</td></tr>
                                        <tr><td>31</td><td>1:796</td></tr>
                                        <tr><td>32</td><td>1:683</td></tr>
                                        <tr><td>33</td><td>1:574</td></tr>
                                        <tr><td>34</td><td>1:474</td></tr>
                                        <tr><td>35</td><td>1:384</td></tr>
                                        <tr><td>36</td><td>1:307</td></tr>
                                        <tr><td>37</td><td>1:242</td></tr>
                                        <tr><td>38</td><td>1:189</td></tr>
                                        <tr><td>39</td><td>1:146</td></tr>
                                        <tr><td>40</td><td>1:112</td></tr>
                                        <tr><td>41</td><td>1:85</td></tr>
                                        <tr><td>42</td><td>1:65</td></tr>
                                        <tr><td>43</td><td>1:49</td></tr>
                                        <tr><td>44</td><td>1:37</td></tr>
                                        <tr><td>45</td><td>1:28</td></tr>
                                        <tr><td>46</td><td>1:21</td></tr>
                                        <tr><td>47</td><td>1:15</td></tr>
                                        <tr><td>48</td><td>1:11</td></tr>
                                        <tr><td>49</td><td>1:8</td></tr>
                                        <tr><td>50</td><td>1:6</td></tr>
                                    </tbody>
                                </table>
                            </div>
                        </div>

                        <div class="table-wrapper">
                            <div class="table-header">
                                <span class="table-icon">üìä</span>
                                <span class="table-caption">Table 10.3 Chromosomal abnormalities by maternal age at the time of amniocentesis performed at 16 weeks' gestation (expressed as rate per 1000)</span>
                            </div>
                            <div class="table-container">
                                <table class="content-table">
                                    <thead>
                                        <tr>
                                            <th>Maternal age (years)</th>
                                            <th>Trisomy 21</th>
                                            <th>Trisomy 18</th>
                                            <th>Trisomy 13</th>
                                            <th>XXY</th>
                                            <th>All chromosomal anomalies</th>
                                        </tr>
                                    </thead>
                                    <tbody>
                                        <tr><td>35</td><td>3.9</td><td>0.5</td><td>0.2</td><td>0.5</td><td>8.7</td></tr>
                                        <tr><td>36</td><td>5.0</td><td>0.7</td><td>0.3</td><td>0.6</td><td>10.1</td></tr>
                                        <tr><td>37</td><td>6.4</td><td>1.0</td><td>0.4</td><td>0.8</td><td>12.2</td></tr>
                                        <tr><td>38</td><td>8.1</td><td>1.4</td><td>0.5</td><td>1.1</td><td>14.8</td></tr>
                                        <tr><td>39</td><td>10.4</td><td>2.0</td><td>0.8</td><td>1.4</td><td>18.4</td></tr>
                                        <tr><td>40</td><td>13.3</td><td>2.8</td><td>1.1</td><td>1.8</td><td>23.0</td></tr>
                                        <tr><td>41</td><td>16.9</td><td>3.9</td><td>1.5</td><td>2.4</td><td>29.0</td></tr>
                                        <tr><td>42</td><td>21.6</td><td>5.5</td><td>2.1</td><td>3.1</td><td>37.0</td></tr>
                                        <tr><td>43</td><td>27.4</td><td>7.6</td><td></td><td>4.1</td><td>45.0</td></tr>
                                        <tr><td>44</td><td>34.8</td><td></td><td></td><td>5.4</td><td>50.0</td></tr>
                                        <tr><td>45</td><td>44.2</td><td></td><td></td><td>7.0</td><td>62.0</td></tr>
                                        <tr><td>46</td><td>55.9</td><td></td><td></td><td>9.1</td><td>77.0</td></tr>
                                        <tr><td>47</td><td>70.4</td><td></td><td></td><td>11.9</td><td>96.0</td></tr>
                                    </tbody>
                                </table>
                            </div>
                        </div>

                        <h4>Clinical risk factors: late pregnancy</h4>
                        <p>The following are risk factors associated with a higher likelihood of fetal abnormality:</p>
                        <ul class="enhanced-list">
                            <li class="list-item">
                                <span class="list-marker"></span>
                                <span class="list-content">persistent breech presentation or abnormal lie</span>
                            </li>
                            <li class="list-item">
                                <span class="list-marker"></span>
                                <span class="list-content">vaginal bleeding, though the majority of pregnant women with vaginal bleeding in pregnancy do not have a fetal abnormality</span>
                            </li>
                            <li class="list-item">
                                <span class="list-marker"></span>
                                <span class="list-content">abnormal fetal movements, both increased and decreased, though for women to be aware of this perhaps subtle difference they usually have to have had a pregnancy previously</span>
                            </li>
                            <li class="list-item">
                                <span class="list-marker"></span>
                                <span class="list-content">abnormal amniotic fluid volume: both polyhydramnios (which is commonly associated with abnormalities of the gastrointestinal system especially obstruction) and oligohydramnios (which is commonly associated with abnormalities of the renal tract such as urethral valves or renal agenesis)</span>
                            </li>
                            <li class="list-item">
                                <span class="list-marker"></span>
                                <span class="list-content">growth restriction though the majority of fetuses that are growth retarded do not have an abnormality.</span>
                            </li>
                        </ul>

                        <h4>Ultrasound</h4>
                        <p>Most pregnant women in the UK present for their first visit to a health professional in the first trimester. This means that they can be offered two early ultrasound (US) scans. The first scan, ideally between 11w+0 d and 13w+6 d, allows fetal viability and number to be confirmed, gestation to be confirmed by crown-rump length (CRL) (see Chapter 4) and, if the woman wishes screening for DS, she can have a measurement of fetal nuchal translucency (NT) (Fig. 10.6) as part of the 'combined testing' programme (see next section).</p>

                        <figure class="content-figure" data-lightbox="true">
                            <div class="figure-image-wrapper">
                                <img src="../assets/images/image-20251213-1d236c1f.jpeg" alt="Nuchal translucency measurement" class="figure-image" loading="lazy">
                                <div class="figure-overlay">
                                    <span class="overlay-icon">üîç</span>
                                    <span class="overlay-text">Click to enlarge</span>
                                </div>
                            </div>
                            <figcaption class="figure-caption">Fig. 10.6 Nuchal translucency measurement (undertaken when CRL = 45‚Äì84 mm). NT measurement: strict sagittal view appropriate for CRL, appropriate magnification (>70% image), away from the amnion, neutral position of the fetal head, biggest of 3‚Äì5 measurements.</figcaption>
                        </figure>

                        <p>The second US scan is offered to women when they are about 20 weeks. The features recorded at this examination are:</p>
                        <ul class="enhanced-list">
                            <li class="list-item">
                                <span class="list-marker"></span>
                                <span class="list-content">confirmation of fetal viability</span>
                            </li>
                            <li class="list-item">
                                <span class="list-marker"></span>
                                <span class="list-content">measurement of fetal head and abdominal circumferences, biparietal diameter, and femur length</span>
                            </li>
                            <li class="list-item">
                                <span class="list-marker"></span>
                                <span class="list-content">amniotic fluid volume</span>
                            </li>
                            <li class="list-item">
                                <span class="list-marker"></span>
                                <span class="list-content">anatomical survey which seeks to confirm a normal appearance in a number of organ systems listed below. The success at identifying structural abnormalities in these systems at about 20 weeks varies and the approximate rates of detection with US reported in 2000 are:
                                    <ul style="margin-top: 0.5rem; margin-bottom: 0;">
                                        <li>cardiac (25%)</li>
                                        <li>central nervous system (60‚Äì90% depending on the specific abnormality)</li>
                                        <li>skeletal (90%)</li>
                                        <li>gastrointestinal (60‚Äì90% depending on the specific abnormality)</li>
                                        <li>urogenital (85%)</li>
                                        <li>pulmonary (60%).</li>
                                    </ul>
                                </span>
                            </li>
                        </ul>

                        <h4>Biochemistry</h4>
                        <p>The accuracy of risk prediction of DS is greatly increased with the combined use of NT with biochemical markers. The 'combined screening test' that should be offered to all women comprises NT, plus assay of Œ≤-human chorionic gonadotrophin (Œ≤hCG) and pregnancy-associated plasma protein-A. This should occur when the CRL measures from 45‚Äì84 mm (at approximately 11w+0 d to 13w+6 d). For each of these three parameters the likelihood of a DS fetus, given the background risk from the woman's age, is calculated against a database of over 200 000 pregnancies with known fetal DS status. The three likelihood ratios can be merged into a single risk to give the individual woman.</p>
                        <p>Where a woman presents in the second trimester, serum screening can be offered between 14 weeks+2 days and 20 weeks and 0 days using the quadruple test. The four chemicals measured are human chorionic gonadotrophin (hCG), Œ±-fetoprotein (aFP), unconjugated oestriol (uE3) and inhibin-A. Again individual likelihood ratios for a DS fetus are calculated for each (given the background risk from the woman's age) and combined into a single risk estimate.</p>
                        <p>The recommendation from the UK National Screening Committee is that a DS risk of greater than 1:150 indicates a 'high' risk and that further assessment in the form of chorionic villus sampling (CVS) in the first trimester or amniocentesis in the second trimester should be discussed with the woman and her partner. In practice, many prefer to present the risk estimate to the woman and allow her to make her own decision.</p>

                        <h4>Counselling in advance of US and biochemical testing</h4>
                        <p>Before a woman participates in any screening programme aimed at detecting fetal abnormalities it is imperative that she has appropriate pre-test counselling. This should cover the following:</p>
                        <ul class="enhanced-list">
                            <li class="list-item">
                                <span class="list-marker"></span>
                                <span class="list-content">emphasizing that the great majority of newborn babies are normal and that only a very small minority have an abnormality</span>
                            </li>
                            <li class="list-item">
                                <span class="list-marker"></span>
                                <span class="list-content">ensuring an understanding of the condition(s) that might be detected with the screening programme</span>
                            </li>
                            <li class="list-item">
                                <span class="list-marker"></span>
                                <span class="list-content">understanding:
                                    <ul style="margin-top: 0.5rem; margin-bottom: 0;">
                                        <li>the limitations of the screening programme including the chances of missing an abnormality</li>
                                        <li>What a 'normal' or 'negative' screening test means</li>
                                        <li>What an 'abnormal' or 'positive' screening test means</li>
                                        <li>What are the practical options if the screening test is 'abnormal' or 'positive'.</li>
                                    </ul>
                                </span>
                            </li>
                        </ul>

                        <h4>Management options with an 'abnormal' or 'positive' test</h4>
                        <h5>Further counselling</h5>
                        <p>Women (with their partner) with an abnormal/positive test should be seen as soon as possible by a health professional with the appropriate expertise and training for ongoing counselling and management. This will either be an obstetrician with a special interest in fetal problems or a fetal medicine subspecialist. The first priority is for the woman and her partner to have non-directive counselling covering:</p>
                        <ul class="enhanced-list">
                            <li class="list-item">
                                <span class="list-marker"></span>
                                <span class="list-content">what they have been told</span>
                            </li>
                            <li class="list-item">
                                <span class="list-marker"></span>
                                <span class="list-content">what they think the abnormal/positive test means</span>
                            </li>
                            <li class="list-item">
                                <span class="list-marker"></span>
                                <span class="list-content">what the abnormal/positive test actually means</span>
                            </li>
                            <li class="list-item">
                                <span class="list-marker"></span>
                                <span class="list-content">what the options are.</span>
                            </li>
                        </ul>

                        <h5>Further assessment</h5>
                        <p>It may be appropriate for the couple to consider further assessment in the form of:</p>
                        <ul class="enhanced-list">
                            <li class="list-item">
                                <span class="list-marker"></span>
                                <span class="list-content">For women with an increased risk of a chromosomal abnormality, an invasive test such as a chorionic villus biopsy/sampling (Fig. 10.7) if the woman presents in the first trimester or an amniocentesis (Fig. 10.8) if the woman presents in the second trimester. Before undertaking the procedure, the woman should be informed that it is undertaken aseptically, will provide information about chromosome number and structure but that it carries a risk of miscarriage (about 1%).</span>
                            </li>
                            <li class="list-item">
                                <span class="list-marker"></span>
                                <span class="list-content">For women suspected to have a structural fetal abnormality, further imaging to clarify the diagnosis either in the form of further US examinations after 1‚Äì2 weeks (to allow for fetal growth and better visualization of fetal anatomy) or an MRI scan (especially useful with abnormalities of the central nervous system). If the anatomical appearances suggest the fetus has a chromosomal abnormality, a CVS (which is more accurately termed placental biopsy at this stage of pregnancy) or amniocentesis could be offered.</span>
                            </li>
                        </ul>

                        <figure class="content-figure" data-lightbox="true">
                            <div class="figure-image-wrapper">
                                <img src="../assets/images/image-20251213-03d2dc0e.jpeg" alt="Chorionic villus sampling" class="figure-image" loading="lazy">
                                <div class="figure-overlay">
                                    <span class="overlay-icon">üîç</span>
                                    <span class="overlay-text">Click to enlarge</span>
                                </div>
                            </div>
                            <figcaption class="figure-caption">Fig. 10.7 Chorionic villus sampling (US visualization is mandatory and undertaken in a similar way to that shown for amniocentesis in Fig 10.8A).</figcaption>
                        </figure>

                        <figure class="content-figure" data-lightbox="true">
                            <div class="figure-image-wrapper">
                                <img src="../assets/images/image-20251213-2d2aab74.jpeg" alt="Amniocentesis" class="figure-image" loading="lazy">
                                <div class="figure-overlay">
                                    <span class="overlay-icon">üîç</span>
                                    <span class="overlay-text">Click to enlarge</span>
                                </div>
                            </div>
                            <figcaption class="figure-caption">Fig. 10.8 Amniocentesis. (A) Simultaneous ultrasound (US) visualization; (B) US image with needle (arrow).</figcaption>
                        </figure>

                        <h5>Options for pregnancy</h5>
                        <p>Once a fetal abnormality is diagnosed with a high chance of death or serious disability, after counselling, the parents may feel that they do not wish to continue with the pregnancy and opt for a termination. However, faced with the same facts other parents may decide to continue with the pregnancy. The decision is for the parents to make and no one else, hence the need for 'non-directive' counselling.</p>

                        <h5>Possible interventions</h5>
                        <p>With some fetal abnormalities a woman and her partner may be offered interventions aimed at improving or ameliorating the fetal condition. Examples include:</p>
                        <ul class="enhanced-list">
                            <li class="list-item">
                                <span class="list-marker"></span>
                                <span class="list-content">Maternally administered anti-arrhythmic drugs to treat fetal cardiac arrhythmias.</span>
                            </li>
                            <li class="list-item">
                                <span class="list-marker"></span>
                                <span class="list-content">Insertion of a vesicoamniotic drain into the fetal bladder to by-pass urethral obstruction in cases of urethral valves to prevent further renal back-pressure and damage.</span>
                            </li>
                        </ul>

                        <h5>Surveillance in pregnancy</h5>
                        <p>All women who decide to continue with the pregnancy with a fetal abnormality will need to be seen regularly for support and counselling by a small number of health professionals who are aware of the diagnosis. In specific cases there will be a need to undertake regular US examinations to assess whether complications of the abnormality are developing and warrant intervention (see above).</p>

                        <h5>Delivery issues</h5>
                        <p>Delivery issues may include:</p>
                        <ul class="enhanced-list">
                            <li class="list-item">
                                <span class="list-marker"></span>
                                <span class="list-content">In advance of the delivery deciding on the place of birth on the basis of the baby's likely need of resources after birth, e.g. neonatal intensive care or surgery, and arranging for the relevant neonatal medical professionals to meet the parents.</span>
                            </li>
                            <li class="list-item">
                                <span class="list-marker"></span>
                                <span class="list-content">Arranging elective delivery if it is considered desirable that the baby would benefit from delivery during the working day and week when full neonatal resources are available.</span>
                            </li>
                            <li class="list-item">
                                <span class="list-marker"></span>
                                <span class="list-content">With some fetal abnormalities it is preferable to avoid a vaginal birth, e.g. there may be a greater risk of fetal trauma such as in a case of fetal hydrocephalus.</span>
                            </li>
                        </ul>
                    </div>
                </section>

                <!-- Assessing Health of Normally Formed Fetus -->
                <section id="assessing-normal-fetus" class="content-section">
                    <div class="section-header">
                        <div class="section-number" aria-hidden="true">03</div>
                        <h2 class="section-title">
                            <span class="title-icon">ü©∫</span>
                            ASSESSING THE HEALTH OF A NORMALLY FORMED FETUS
                        </h2>
                    </div>
                    
                    <div class="content-card">
                        <h3>Screening for fetal health</h3>
                        <p>In contrast to the screening offered to pregnant women to assess their risk of fetal abnormality, what is offered to identify the unhealthy fetus is limited. It relies initially on identification of clinical risk factors associated with a greater risk of fetal compromise. Women with no risk factors for fetal compromise ('low risk') have:</p>
                        <ul class="enhanced-list">
                            <li class="list-item">
                                <span class="list-marker"></span>
                                <span class="list-content">Maternal vigilance for fetal activity over second half of pregnancy.</span>
                            </li>
                            <li class="list-item">
                                <span class="list-marker"></span>
                                <span class="list-content">Fundal height measurement at every antenatal clinic visit. This involves measuring the distance between the maternal symphysis pubis and uterine fundus (see Fig. 6.12). The reverse blank side of tape measure uppermost and the distance (in cm) is read after it has been determined by turning the tape measure over. The normal range between 16‚Äì36 weeks is (gestational age in ¬± 3 cm). Thus at 32 weeks the normal range is 32 ¬± 3 cm.</span>
                            </li>
                            <li class="list-item">
                                <span class="list-marker"></span>
                                <span class="list-content">Auscultation of the fetal heart at every antenatal clinic visit. This is undertaken either using a pinard stethoscope (Fig. 10.9A) or a handheld Doppler US device (Fig. 10.9B). In routine practice, the rate is not recorded just a note that the fetal heart is beating. Thus, abnormalities of the fetal baseline heart rate may be missed.</span>
                            </li>
                        </ul>
                        <p>Women with risk factors ('high risk') have customized surveillance that is determined by the presumed underlying pathophysiology. The more common examples are shown in Table 10.4.</p>

                        <figure class="content-figure" data-lightbox="true">
                            <div class="figure-image-wrapper">
                                <img src="../assets/images/image-20251213-30888a1a.jpeg" alt="Auscultation of the fetal heart" class="figure-image" loading="lazy">
                                <div class="figure-overlay">
                                    <span class="overlay-icon">üîç</span>
                                    <span class="overlay-text">Click to enlarge</span>
                                </div>
                            </div>
                            <figcaption class="figure-caption">Fig. 10.9 Auscultation of the fetal heart (the aim is to place the stethoscope/transducer as close to the fetal heart as possible). If the fetal back is anterior the best site is over the left fetal scapula. If the fetal back is posterior the best site is around the maternal umbilicus). (A) Using the pinard stethoscope; (B) using a handheld Doppler US recording device.</figcaption>
                        </figure>

                        <div class="table-wrapper">
                            <div class="table-header">
                                <span class="table-icon">üìä</span>
                                <span class="table-caption">Table 10.4 Risk factors for fetal compromise</span>
                            </div>
                            <div class="table-container">
                                <table class="content-table">
                                    <thead>
                                        <tr>
                                            <th>Type of risk</th>
                                            <th>Risk factor/problem</th>
                                            <th>Presumed pathophysiology</th>
                                            <th>Surveillance</th>
                                        </tr>
                                    </thead>
                                    <tbody>
                                        <tr>
                                            <td>Specific</td>
                                            <td>Maternal vascular disease, e.g. hypertension, antiphospholipid or lupus antibodies</td>
                                            <td>Uteroplacental vascular disease (UPVD), i.e. poor blood flow to and within the placenta with associated reduced gaseous and nutritional transfer</td>
                                            <td>Maternal vigilance for fetal movements<br>Umbilical artery Doppler recordings<br>US monitoring of fetal growth Biophysical assessment if any of these not normal</td>
                                        </tr>
                                        <tr>
                                            <td></td>
                                            <td>Maternal diabetes</td>
                                            <td>The pathophysiology of fetal risk is uncertain</td>
                                            <td>The same package of surveillance is used as in women with UPVD, but it is less effective at predicting fetal death</td>
                                        </tr>
                                        <tr>
                                            <td></td>
                                            <td>Twins</td>
                                            <td>Main risks are:<br>For all twins: fetal growth restriction form UPVD<br>For monochorionic twins: the twin-twin transfusion syndrome (TTTS), i.e. shared placental circulation with risk of one fetus being the 'donor' and the other being the 'recipient'</td>
                                            <td>For fetal growth restriction:<br>- Fetal surveillance as in women at risk of UPVD (see above)<br>For TTTS, monitoring of monochorionic twins to look for signs of TTTS:<br>- Amniotic fluid volume (AFV) raised in one twin (recipient) and reduced in the other (donor)<br>- Absence of urine in fetal bladders<br>- Abnormal umbilical artery Doppler recording in either fetus</td>
                                        </tr>
                                        <tr>
                                            <td></td>
                                            <td>Isoimmunization due to Rhesus antibodies</td>
                                            <td>Transplacental passage of maternal antibodies (anti-D or Kell or Duffy) causing severe fetal anaemia</td>
                                            <td>With fetal anaemia the fetal middle cerebral artery blood flow is raised with anaemia and confirmed by fetal blood sampling (FBS)</td>
                                        </tr>
                                        <tr>
                                            <td>Non-specific</td>
                                            <td>Previous fetal death<br>Previous fetal growth restriction<br>Maternal perception of reduced fetal movements<br>Vaginal bleeding<br>Abdominal pain</td>
                                            <td>A variety of pathologies result in fetal death, fetal growth restriction, reduced movements, vaginal bleed and abdominal pain. Unless the cause is known the normal approach initially is to assume it is UPVD</td>
                                            <td>Fetal surveillance as in women at risk of UPVD (see above) In women with reduced FM, ongoing surveillance is only needed where the FM do not return to normal<br>In women with vaginal bleeding or abdominal pain ongoing surveillance is needed only where the symptoms persist</td>
                                        </tr>
                                        <tr>
                                            <td></td>
                                            <td>Abnormal uterine size and/ or growth (larger or smaller than normal)</td>
                                            <td>Many cases of clinically suspected abnormal fetal growth are not confirmed with US. If confirmed, a variety of pathologies result in fetal growth restriction. Unless cause is known the normal approach is to assume it is UPVD</td>
                                            <td>If abnormal fetal size/growth confirmed with US, fetal assessment as in women at risk of UPVD (see above)</td>
                                        </tr>
                                    </tbody>
                                </table>
                            </div>
                        </div>

                        <h3>Surveillance of fetal health in at-risk pregnancies</h3>
                        <p>On the basis of the clinical risk assessment screening (above) an individualized programme of fetal surveillance will be offered to 'at risk' women during their pregnancy. The most commonly used methods are discussed here.</p>

                        <h4>Doppler recordings of blood flow in the umbilical artery (UA)</h4>
                        <p>This investigation has been shown to significantly improve fetal outcome in high-risk pregnancies. Figure 10.10A shows a normal recording.</p>
                        <p>Figure 10.10B shows an example of 'absent end-diastolic flow' (AEDV). The commonest explanation is an increase in placental vascular resistance ('downstream' from the point of recording), which is typical of umbilical placental vascular disease (UPVD). The prognosis for the fetus with AEDV is worse with growth restriction, hypoxia and death all being commoner. However, the risk is not usually immediate and management options include continued close surveillance with biophysical testing until a viable gestational age is reached or the biophysical testing is abnormal. If this abnormality occurs at 34 weeks or beyond most would offer the woman elective preterm delivery rather than continuing the pregnancy and the possibility of fetal death.</p>
                        <p>Figure 10.10C shows an example of 'reversed diastolic flow'. This is an even more ominous feature and is associated with a much higher chance of imminent fetal death. Management will depend on gestational age. If the pregnancy is at 26 weeks or more then elective preterm delivery (with the attendant risks of prematurity) compared with continuing the pregnancy (and the high risk of fetal death) has to be discussed with the parents. If the pregnancy is less than 26 weeks the discussions are more difficult and the parents may opt for no intervention.</p>

                        <figure class="content-figure" data-lightbox="true">
                            <div class="figure-image-wrapper">
                                <img src="../assets/images/image-20251213-ce61baa9.jpeg" alt="Doppler ultrasound recording of umbilical artery blood flow" class="figure-image" loading="lazy">
                                <div class="figure-overlay">
                                    <span class="overlay-icon">üîç</span>
                                    <span class="overlay-text">Click to enlarge</span>
                                </div>
                            </div>
                            <figcaption class="figure-caption">Fig. 10.10 Doppler ultrasound recording of umbilical artery blood flow. (A) Normal. Note: the left US image shows the UA with red and blue colours indicating blood flow. The right US image is the Doppler recording taken from that UA. The peak of the wave represents the peak of the systolic phase and the trough the diastolic phase of the fetal cardiac cycle respectively. In the normal fetoplacental circulation there is always forward flow even when the heart is not contracting because there is a low resistance to flow within the placental circulation. (B) Abnormal - absent end diastolic flow. Note: there is no forward flow during diastoly for most of the cardiac cycles. (C) Abnormal - reversed diastolic flow. Note: there is forward flow of blood in the UA during systoly but the direction of flow reverses in diastoly.</figcaption>
                        </figure>

                        <h4>Fetal growth</h4>
                        <p>Fetal growth is best documented in pregnancy using serial US measurements of head (HC) and abdominal (AC) circumferences.</p>

                        <h5>Small fetuses</h5>
                        <p>Three patterns of suboptimal fetal growth are recognized. Once the AC is on or below the lowest centile, the fetus is termed 'small-for-dates'.</p>
                        <p>Figure 10.11A illustrates a constitutionally small fetus. Genetic factors contribute to this pattern. Typically the mother will be short and/or of Asian ethnicity. If multiparous, her previous baby(ies) may have been small. Whilst this fetus is not at such a high risk of complications as in the pathologically small fetus (see below), those risks are still greater compared to a normally grown fetus.</p>
                        <p>Figure 10.11B and C represent fetal growth patterns that are due to a pathological cause. They represent different points on the spectrum of fetal growth restriction. The asymmetrical type tends to occur later in pregnancy and is more commonly associated with conditions such as UPVD in the last trimester, whereas the symmetrical type tends to represent a pathological insult that operated from an early point in pregnancy, e.g. fetal abnormality, severe early onset pre-eclampsia. Both are associated with a higher risk of fetal death and hypoxia, preterm delivery and placental bleeding.</p>

                        <figure class="content-figure" data-lightbox="true">
                            <div class="figure-image-wrapper">
                                <img src="../assets/images/image-20251213-a17bf7f0.jpeg" alt="Fetal growth patterns A and B" class="figure-image" loading="lazy">
                                <div class="figure-overlay">
                                    <span class="overlay-icon">üîç</span>
                                    <span class="overlay-text">Click to enlarge</span>
                                </div>
                            </div>
                            <figcaption class="figure-caption">Fig. 10.11 Fetal growth patterns detected using ultrasound. (A) Constitutionally small fetus. Note: both HC and AC follow the lowest growth trajectories. (B) Asymmetrically small fetus. Note: the HC follows a normal trajectory whilst the AC crosses trajectories and eventually falls outside the normal range.</figcaption>
                        </figure>

                        <figure class="content-figure" data-lightbox="true">
                            <div class="figure-image-wrapper">
                                <img src="../assets/images/image-20251213-e980c16d.jpeg" alt="Fetal growth pattern C" class="figure-image" loading="lazy">
                                <div class="figure-overlay">
                                    <span class="overlay-icon">üîç</span>
                                    <span class="overlay-text">Click to enlarge</span>
                                </div>
                            </div>
                            <figcaption class="figure-caption">Fig. 10.11 Continued (C) Symmetrically small fetus. Note: both HC and AC fall away from the normal growth trajectories. Such head growth compromise carries a greater likelihood of developmental delay in childhood.</figcaption>
                        </figure>

                        <h5>Big fetuses</h5>
                        <p>In an analogous way to small fetuses, large fetuses can either be:</p>
                        <ul class="enhanced-list">
                            <li class="list-item">
                                <span class="list-marker"></span>
                                <span class="list-content">Constitutionally large ('large-for-dates') with the HC and AC growth trajectories both following the top centile line. Typically the woman would be tall and/ or of Afro-Caribbean ethnicity.</span>
                            </li>
                            <li class="list-item">
                                <span class="list-marker"></span>
                                <span class="list-content">Pathologically large ('macrosomia') with the HC growth trajectory following a centile in the normal range but the AC growth trajectory demonstrates accelerated growth upwards across centiles. This pattern of growth is most commonly seen in fetuses of diabetic women.</span>
                            </li>
                        </ul>

                        <h4>Amniotic fluid volume (AFV)</h4>
                        <p>The most accurate estimate of AFV is with US. Two methods are used:</p>
                        <ul class="enhanced-list">
                            <li class="list-item">
                                <span class="list-marker"></span>
                                <span class="list-content">Single deepest pocket (the normal range is 2‚Äì8 cm).</span>
                            </li>
                            <li class="list-item">
                                <span class="list-marker"></span>
                                <span class="list-content">Amniotic fluid index (AFI) which is the sum of the depths of the pools of amniotic fluid in each of the 4 quadrants of the uterus (top right and left and bottom right and left). Figure 10.12 shows the normal range of the AFI during pregnancy.</span>
                            </li>
                        </ul>

                        <figure class="content-figure" data-lightbox="true">
                            <div class="figure-image-wrapper">
                                <img src="../assets/images/image-20251213-8bee1c08.jpeg" alt="Amniotic fluid index graph" class="figure-image" loading="lazy">
                                <div class="figure-overlay">
                                    <span class="overlay-icon">üîç</span>
                                    <span class="overlay-text">Click to enlarge</span>
                                </div>
                            </div>
                            <figcaption class="figure-caption">Fig. 10.12 Amniotic fluid index.</figcaption>
                        </figure>

                        <h4>Biophysical measurements</h4>
                        <p>The behaviour of a fetus is a useful indicator of his/her immediate wellbeing. With most fetal pathologies, these parameters are affected relatively late in the process. The five observations used in practice are:</p>
                        <ul class="enhanced-list">
                            <li class="list-item">
                                <span class="list-marker"></span>
                                <span class="list-content"><strong>Fetal heart rate (FHR):</strong> this is recorded with a cardiotocograph (CTG) (as in labour). The maximum recording time is 40 minutes and in that time there should be at least 2 accelerations of the FHR by 15 beats/min or more and lasting for at least 15 seconds. The patterns of heart rate change are similar to those described in labour (see Chapter 11) with the difference that uterine activity is minimal and more emphasis is therefore placed on the interpretation of baseline heart rate. An example of a normal antenatal CTG is shown in Figure 10.13. This shows a baseline variability of more than 5 beats/min with accelerations and no decelerations. Figure 10.14 shows a normal baseline rate but reduced baseline variability.</span>
                            </li>
                            <li class="list-item">
                                <span class="list-marker"></span>
                                <span class="list-content"><strong>Fetal movements:</strong> there should be at least 3 separate/ discreet movements in 40 minutes of fetal observation with US.</span>
                            </li>
                            <li class="list-item">
                                <span class="list-marker"></span>
                                <span class="list-content"><strong>Fetal tone:</strong> at least one of these fetal movements should demonstrate a full 90¬∞ flexion-extensionflexion cycle.</span>
                            </li>
                            <li class="list-item">
                                <span class="list-marker"></span>
                                <span class="list-content"><strong>Fetal breathing:</strong> there should be a sustained 30 second period of regular fetal breathing movements during the 40 minute observation period.</span>
                            </li>
                            <li class="list-item">
                                <span class="list-marker"></span>
                                <span class="list-content"><strong>AFV:</strong> there should be at least one vertical pool measuring between 2 and 8 cm.</span>
                            </li>
                        </ul>
                        <p>The use of all five parameters in combination is called 'the biophysical profile' or 'score' (BPP or BPS). A normal response is for the fetus to exhibit at least 4 of these parameters in a period of up to 40 minutes (they may be seen in a much shorter period). The original BPS was recorded over 30 minutes but that did not take account of the possibility of normal fetal 'sleep' which can last up to 40 minutes and during which no movements, accelerations, or breathing may be seen, hence the change to an observation window of 40 minutes.</p>

                        <figure class="content-figure" data-lightbox="true">
                            <div class="figure-image-wrapper">
                                <img src="../assets/images/image-20251213-b1ce3f65.jpeg" alt="Normal antenatal cardiotocograph" class="figure-image" loading="lazy">
                                <div class="figure-overlay">
                                    <span class="overlay-icon">üîç</span>
                                    <span class="overlay-text">Click to enlarge</span>
                                </div>
                            </div>
                            <figcaption class="figure-caption">Fig. 10.13 Normal antenatal cardiotocograph. The recording shows a baseline variability of &gt;5 beats/min and episodes of accelerations.</figcaption>
                        </figure>

                        <figure class="content-figure" data-lightbox="true">
                            <div class="figure-image-wrapper">
                                <img src="../assets/images/image-20251213-4993ac82.jpeg" alt="Antenatal cardiotocograph showing reduced variability" class="figure-image" loading="lazy">
                                <div class="figure-overlay">
                                    <span class="overlay-icon">üîç</span>
                                    <span class="overlay-text">Click to enlarge</span>
                                </div>
                            </div>
                            <figcaption class="figure-caption">Fig. 10.14 Antenatal cardiotocograph showing a normal heart rate but reduced baseline variability.</figcaption>
                        </figure>
                    </div>
                </section>

                <!-- Interventions -->
                <section id="interventions" class="content-section">
                    <div class="section-header">
                        <div class="section-number" aria-hidden="true">04</div>
                        <h2 class="section-title">
                            <span class="title-icon">üõ†Ô∏è</span>
                            INTERVENTIONS
                        </h2>
                    </div>
                    
                    <div class="content-card">
                        <h3>Non-specific risk</h3>
                        <p>When a theoretic risk to the fetus is proven to be real by fetal surveillance, the only two interventions of value are:</p>
                        <ul class="enhanced-list">
                            <li class="list-item">
                                <span class="list-marker"></span>
                                <span class="list-content"><strong>Elective delivery:</strong> if the risk is identified at 34 or more weeks then there is usually no reason to delay the delivery. Where the risk is identified before 34 weeks the management is determined by the assessment of immediate risk of fetal death. Thus, if the BPS or CTG (acute measures of health) are abnormal and/or there is reversed end diastolic flow in the umbilical artery then delivery without delay is discussed with the parents. Where there is no abnormality in these parameters, then continued close monitoring could continue to 'gain' time in the pregnancy and allow the maternal administration of steroids.</span>
                            </li>
                            <li class="list-item">
                                <span class="list-marker"></span>
                                <span class="list-content"><strong>Maternal steroids:</strong> if it is clear that elective preterm delivery is likely to occur in an at risk pregnancy but only the chronic measures of fetal health are abnormal, e.g. suboptimal growth and absent umbilical artery Doppler diastolic recordings, then the woman would be advised to have a course of betamethasone.</span>
                            </li>
                        </ul>

                        <h3>Specific risk</h3>
                        <p>These are relatively uncommon and include:</p>
                        <ul class="enhanced-list">
                            <li class="list-item">
                                <span class="list-marker"></span>
                                <span class="list-content">maternal drugs for fetal cardiac arrhythmias</span>
                            </li>
                            <li class="list-item">
                                <span class="list-marker"></span>
                                <span class="list-content">intrauterine blood transfusion for fetuses with severe Rhesus isoimmunization</span>
                            </li>
                            <li class="list-item">
                                <span class="list-marker"></span>
                                <span class="list-content">laser ablation of placental vascular communications in twin-to-twin transfusion syndrome.</span>
                            </li>
                        </ul>
                    </div>
                </section>

                <!-- Conclusions -->
                <section id="conclusions" class="content-section">
                    <div class="section-header">
                        <h2 class="section-title">
                            <span class="title-icon">üîö</span>
                            CONCLUSIONS
                        </h2>
                    </div>
                    <div class="content-card">
                        <ul class="enhanced-list">
                            <li class="list-item">
                                <span class="list-marker"></span>
                                <span class="list-content">Most, though not all, fetuses with structural or chromosomal abnormality are identified during pregnancy with current screening programmes.</span>
                            </li>
                            <li class="list-item">
                                <span class="list-marker"></span>
                                <span class="list-content">In normally formed fetuses, once risk is identified, both specific and non-specific, the current methods of surveillance coupled with the judicious use of maternal steroid administration and elective delivery are effective in the sense that most fetuses identified to be 'at risk' will not die in utero.</span>
                            </li>
                            <li class="list-item">
                                <span class="list-marker"></span>
                                <span class="list-content">In normally formed fetuses that are apparently at no risk the current method of routine surveillance during pregnancy (maternal perception of fetal movements, fundal height measurement and auscultation of the fetal heart) is limited and does not identify all fetuses that are genuinely at risk.</span>
                            </li>
                        </ul>
                    </div>
                </section>

                <!-- Essential Information -->
                <aside class="key-points-section" role="region" aria-labelledby="key-points-title">
                    <div class="key-points-wrapper">
                        <div class="key-points-header">
                            <span class="key-points-icon">‚≠ê</span>
                            <h3 id="key-points-title" class="key-points-title">Essential information</h3>
                        </div>
                        <ul class="key-points-list">
                            <li class="key-point-item">
                                <span class="point-marker">‚úì</span>
                                <p><strong>Congenital Abnormalities</strong>:
                                    <ul style="margin-top: 0.5rem; margin-bottom: 0; color: white;">
                                        <li>Fetal abnormality is found in: over 50% of conceptions; about 70% of miscarriages; 15% of deaths between 20 weeks and 1 year postnatal; 1‚Äì2% of births (major and minor anomalies); 8% of special needs register/disabled children.</li>
                                        <li>The overall UK incidence has fallen over the past 30y due to: Introduction of screening programmes in pregnancy; Greater success at diagnosis during pregnancy; Parents choosing pregnancy termination.</li>
                                        <li>The commonest four groups of defects are: Neural tube defects (3‚Äì7/1000 births); Congenital cardiac defects (6/1000 births); Down's syndrome (1.5/1000 births); Cleft lip/palate (1.5/1000 births).</li>
                                        <li>Screening for fetal abnormality can be undertaken: Clinically in early pregnancy (maternal age, drugs, history); Clinically in late pregnancy (uterine size, movements, lie); Using ultrasound (NT, anatomical survey); Biochemically.</li>
                                        <li>Balanced pre-test counselling is important. Options with an abnormal test include further assessment, specific interventions, termination, or continuation with surveillance.</li>
                                    </ul>
                                </p>
                            </li>
                            <li class="key-point-item">
                                <span class="point-marker">‚úì</span>
                                <p><strong>Assessing the health of a normally formed fetus</strong>:
                                    <ul style="margin-top: 0.5rem; margin-bottom: 0; color: white;">
                                        <li>Surveillance in a low-risk pregnancy comprises: Maternal vigilance for fetal activity; Fundal height measurement; Auscultation of the fetal heart.</li>
                                        <li>Surveillance in a high-risk pregnancy comprises tests depending on pathophysiology. The majority will have combined serial measurements of: Umbilical artery blood flow (Doppler); Fetal growth; Amniotic fluid volume; Biophysical parameters (heart rate, movements, tone, breathing).</li>
                                        <li>Interventions for non-specific risk: Elective delivery; Maternal administration of steroids.</li>
                                        <li>Interventions for specific risk (rare): Maternal anti-arrhythmic drugs; Fetal blood transfusion; Laser ablation for TTTS.</li>
                                    </ul>
                                </p>
                            </li>
                        </ul>
                    </div>
                </aside>
            </div>

            <!-- Bottom Navigation -->
            <nav class="document-nav document-nav--bottom" role="navigation" aria-label="Document navigation">
                <div class="nav-container">
                    <a href="chapter-09-maternal-medicine.html" class="nav-button nav-button--prev nav-button--large">
                        <span class="nav-icon">‚Üê</span>
                        <div class="nav-content">
                            <span class="nav-label">Previous</span>
                            <span class="nav-title">Maternal Medicine</span>
                        </div>
                    </a>
                    
                    <a href="../index.html" class="nav-button nav-button--toc">
                        <span class="nav-icon">üìö</span>
                        <span class="nav-text">All Topics</span>
                    </a>
                    
                    <a href="chapter-11-management-labour.html" class="nav-button nav-button--next nav-button--large">
                        <div class="nav-content">
                            <span class="nav-label">Next</span>
                            <span class="nav-title">Management of Labour</span>
                        </div>
                        <span class="nav-icon">‚Üí</span>
                    </a>
                </div>
            </nav>
        </article>
    </div>
</div>

<!-- Lightbox Modal -->
<div class="lightbox-modal" id="lightbox-modal" role="dialog" aria-modal="true" aria-label="Image viewer" hidden>
    <div class="lightbox-backdrop"></div>
    <div class="lightbox-content">
        <button class="lightbox-close" aria-label="Close image viewer">√ó</button>
        <img class="lightbox-image" src="" alt="">
        <p class="lightbox-caption"></p>
    </div>
</div>

<!-- Scripts -->
<script src="../js/theme.js"></script>
<script src="../js/navigation.js"></script>
<script src="../js/interactions.js"></script>